Research monograph · pentapeptide gh secretagogue / ghsr-1a agonist
GH Pulse Studies
This monograph collects what the published literature reports about Ipamorelin — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. It is studied specifically for its selectivity: unlike earlier secretagogues, published work reports minimal effect on cortisol and prolactin at comparable doses, which is why it appears so often in growth-hormone pulse research.
For laboratory research use only — not for human or animal use
Mechanisms
Ghrelin Receptor Activation
Binding is selective for GHSR-1a on anterior pituitary somatotrophs, which is the receptor population that releases growth hormone. Selectivity at that site is the compound's defining property.
No Cortisol or Prolactin Elevation
At doses producing substantial growth hormone release, published work reports no meaningful rise in ACTH, cortisol or prolactin — the off-target effects that limited earlier secretagogues in the same class.
Physiologic GH Secretion Pattern
Release occurs in discrete bursts rather than as a sustained elevation, matching the pattern of endogenous secretion. Whether pulse shape matters as much as total exposure is an open question the literature keeps returning to.
Studied applications
Selectivity is the property under study: growth hormone release without the cortisol and prolactin rise earlier secretagogues produced.
Raun et al. 1998
Endogenous release peaks during slow-wave sleep, so sleep-phase dosing is a recurring variable in the protocols.
Frieboes et al. 2004
Bone mineral density and longitudinal growth are measured in rodent models as downstream consequences of altered release.
Raun et al. 1998
Combination work tests whether engaging the ghrelin and GHRH receptors together amplifies the pulse beyond either alone.
Raun et al. 1998
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
|---|---|
| Molecular weight | 711.90 g/mol |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for up to 24 months |
| Solubility | Water-soluble |
| Available sizes | 10mg |
FAQ
Ipamorelin is a five-residue peptide binding GHS-R, the growth hormone secretagogue receptor. It is studied specifically for its selectivity: unlike earlier secretagogues, published work reports minimal effect on cortisol and prolactin at comparable doses, which is why it appears so often in growth-hormone pulse research.
Published research on Ipamorelin concentrates on Selective GH Secretagogue, GH Secretion & Sleep, Bone Growth Models and Synergy with GHRH Analogs. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes Ipamorelin acting across Ghrelin Receptor Activation, No Cortisol or Prolactin Elevation and Physiologic GH Secretion Pattern, reported respectively as GHSR-1a Agonist, Selectivity and Pulsatile GH. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
Ipamorelin has a molecular formula of C38H49N9O5, an average mass of 711.85 g/mol and the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It is indexed under CAS 170851-70-4. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Ipamorelin is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. Ipamorelin is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
